Check Before You Invest : Accretion Nutraveda Ltd

Q: Which industry/sub-sector does Accretion Nutraveda Ltd belong to?

Accretion Nutraveda Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Accretion Nutraveda Ltd a good quality company?

Accretion Nutraveda Ltd is a weak quality company, based on a inconsistent multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Accretion Nutraveda Ltd undervalued or overvalued?

Accretion Nutraveda Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 37.56, Historic Median: 54.03. Price to Book, Current: 5.37, Historic Median: 4.08. Price to Sales, Current: 5.67, Historic Median: 8.82. EV to EBITDA, Current: 27.73, Historic Median: 38.40

Q: Is Accretion Nutraveda Ltd a good buy now?

Accretion Nutraveda Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Q: Gross Profit margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Gross profit margin which is the profit after deduction of direct costs, is 21.4% for FY-2025, which is in line with its 3-year median of 21.4%, indicating stable margins.

Q: Operating Profit Margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 23.26% for FY-2025, which is in line with its 3-year median of 23.26% indicating stable margins.

Q: Net Profit Margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Net Profit Margin is 16.33% for FY-2025, is in line with its 3-year median of 16.33%, indicating stable margins. Profitability Metrics. Gross Profit Margin (%), Current: 21.4, Historic Median: 21.4. Operating Profit Margin (%), Current: 23.26, Historic Median: 23.26. Net Profit Margin (%), Current: 16.33, Historic Median: 16.33

Q: Return on Asset of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on Asset is 33.71%, which is above its 3-year historical median of 18.9%, indicating improved asset utilization efficiency.

Q: Return on capital employed (ROCE) of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on capital employed is 56.72% for FY-2025, which is above its 3-year historical median of 42%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q: Return on Equity (ROE) of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on equity is 81.22% for FY-2025, which is below its 3-year historical median of 106.65%, indicating the business is making worse use of its shareholders capital.

Check Before You Invest : Accretion Nutraveda Ltd

Snapshot

Q.1 Which industry/sub-sector does Accretion Nutraveda Ltd belong to?

Accretion Nutraveda Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Accretion Nutraveda Ltd a good quality company?

Accretion Nutraveda Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Accretion Nutraveda Ltd undervalued or overvalued?

Accretion Nutraveda Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	3-year Historic Median
Price to Earnings	37.56	54.03
Price to Book	5.37	4.08
Price to Sales	5.67	8.82
EV to EBITDA	27.73	38.40

Q.4 Is Accretion Nutraveda Ltd a good buy now?

Accretion Nutraveda Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

Q.1 Gross Profit margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Gross profit margin which is the profit after deduction of direct costs, is 21.4% for FY-2025, which is in line with its 3-year median of 21.4%, indicating stable margins.

Q.2 Operating Profit Margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 23.26% for FY-2025, which is in line with its 3-year median of 23.26% indicating stable margins.

Q.3 Net Profit Margin of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Net Profit Margin is 16.33% for FY-2025, is in line with its 3-year median of 16.33%, indicating stable margins.

	Current Level	3-year Historic Median
Gross Profit Margin (%)	21.4	21.4
Operating Profit Margin (%)	23.26	23.26
Net Profit Margin (%)	16.33	16.33

B: Does the business utilize capital efficiently?

Q.4 Return on Asset of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on Asset is 33.71%, which is above its 3-year historical median of 18.9%, indicating improved asset utilization efficiency.

Q.5 Return on capital employed (ROCE) of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on capital employed is 56.72% for FY-2025, which is above its 3-year historical median of 42%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.6 Return on Equity (ROE) of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Return on equity is 81.22% for FY-2025, which is below its 3-year historical median of 106.65%, indicating the business is making worse use of its shareholders capital.

C: How much debt does the business have and is it at a sustainable level?

Q.7 Debt to Equity ratio of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Debt-to-Equity ratio is 0.72, which is above the industry average of 0.14, indicating higher debt levels in the industry.

Q.8 Debt to cash flow from operations of Accretion Nutraveda Ltd?

Accretion Nutraveda Ltd Debt to cash flow from operations is -1.74, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Accretion Nutraveda Ltd?

Q.1 Promoter shareholding and pledge status of Accretion Nutraveda Ltd?

Promoters hold 73.48% of the Accretion Nutraveda Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Accretion Nutraveda Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Accretion Nutraveda Ltd vs industry peers?

Accretion Nutraveda Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 6.81%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	3-year Industry Median
Revenue Growth (%)	-	6.8
Gross Profit Growth (%)	200	12.6
Operating Profit Growth (%)	300	9.5
Net Profit Growth (%)	200	8.6

Operating Efficiency

	Current Level	3-year Industry Median
Asset Turnover (x)	2.06	0.75
ROE (%)	81.22	9.05
ROCE (%)	56.72	11.33
Cash Conversion Cycle (days)	93.8	83

Valuation & price assessment

Q.1 Stock return of Accretion Nutraveda Ltd over the last decade?

Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	-

Q.2 Valuation ratios of Accretion Nutraveda Ltd vs historical?

The current P/E ratio of 37.56 is lower than its historical median of 54.03, indicating that the stock is trading below its historical average valuation.

Q.3 How do the current valuation ratios compare with 3-year historical median and industry numbers?

Valuation Ratios	Current	3-year Historic Median	3-year Industry Median
Price to Earnings	37.56	54.03	33.73
Price to Book	5.37	4.08	3.09
Price to Sales	5.67	8.82	3.38
EV to EBITDA	27.73	38.40	16.04

Check more companies

4. Wockhardt

8. Astrazeneca Pharma I

9. Neuland Laboratories

10. Onesource Specialty

Check trending companies

1. Granules India Ltd.

2. Nestle India Ltd.

3. National Aluminium Company Ltd.

4. Muthoot Finance Ltd.

5. Motilal Oswal Financial Services Ltd.

Check Before You Invest : Accretion Nutraveda Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.